Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Cardiology Research

Study Title: Zilver® PTX® V: Drug-Eluting Peripheral Stent Post-Approval Study. (Identifier: NCT01901289)

Study Purpose: The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.

Principal Investigator: Mark Burket, M.D.

Study Coordinator: Jill Sholl, RN, for more information, please contact 419.383.3853.


Study Title:  AMG 145: A Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of AMG 145 Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization. (Identifier: NCT01813422)

Study Purpose: This study will evaluate whether low-density lipoprotein (LDL-C) lowering with AMG 145 results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in subjects with coronary artery disease taking lipid lowering therapy

Principal Investigator: William Coyler, M.D.

Study Coordinator: Chris Eisenhauer, RN BSN, for more information, please contact 419.383.3853


Study Title: Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure. (Identifier: NCT01661634)

Study Purpose: The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).

Principal Investigator: Samer Khouri, M.D.

Study Coordinator: Jill Sholl, RN, for more information, please contact 419.383.3853.


Study Title: Lutonix® Drug coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis (SFA ISR). (Identifier: NCT02063672)

Study Purpose: To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of femoropopliteal artery (SFA) in-stent restenosis (ISR).

Principal Investigator: Mark Burket, M.D.

Study Coordinator: Jill Sholl, RN, for more information, please contact 419.383.3853.


Study Title:  A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR Added-on to treprostinil, inhaled (Tyvaso (r)) in Subjects with Pulmonary Arterial Hypertension

Study Purpose: Patients new to Tyvaso, will enter a run-in period on inhaled treprostinil until 90 days of experience is achieved to ensure drug tolerability before enrolling in the study.

Principal Investigator: George.Moukarbel, MD

Study Coordinator: Chris Eisenhauer, RN BSN, for more information, please contact 419.383.3853

Last Updated: 10/24/14